Advancing transplantation: New questions, new possibilities in kidney and liver transplantation

Jonas Wadström, Bo Göran Ericzon, Philip F. Halloran, Wolf O. Bechstein, Gerhard Opelz, Daniel Serón, Josep Grinyó, Alexandre Loupy, Dirk Kuypers, Christophe Mariat, Marc Clancy, Alan G. Jardine, Lluís Guirado, Bengt Fellström, John O'Grady, Jacques Pirenne, Jacqueline G. O'Leary, Varuna Aluvihare, Pavel Trunečka, Umberto BaccaraniJames Neuberger, Alejandro Soto-Gutierrez, Edward K. Geissler, Monty Metzger, Muir Gray

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Disclosure and contributions: This supplement collects a number of the sessions from the meeting 'Advancing Transplantation: New Questions, New Possibilities'. The meeting was sponsored by Astellas Pharma Europe Ltd; the agenda was developed by Astellas in collaboration with the meeting's scientific committee: J Wadström, BG Ericzon, WO Bechstein, D Serón and PF Halloran. The event was approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 12 category 1 (external) CPD credits. The scientific committee and faculty developed their own content for the meeting with editorial support from iS Health Group. Editorial support for the meeting was funded by Astellas Pharma Europe Ltd. Previously unpublished data that could not be included, due to existing embargo policies or to protect intellectual property, have been excluded from this report. The unpublished data in this report were included at the discretion of the authors as personal communications. Based on the presentations given at the meeting and under the direction of the authors, iS LifeScience provided editorial support throughout the development of this supplement. Editorial support was funded by Astellas Pharma Europe Ltd. A.L., in his role as the Guest Editor, reviewed this supplement and advised on the content throughout the development process. The authors had final authority over the editorial content and approved the final version of this supplement before submission. Astellas Pharma and associated companies developed, manufacture and supply tacrolimus (tacrolimus hard capsules (Prograf), tacrolimus prolonged-release hard capsules (Advagraf)). Prescribing information and adverse event reporting information can be found on pages S40-S41. J.W. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. B-G.E reports nonfinancial support from Astellas, during the development of this supplement; honoraria and consultancy fees from Astellas, Pfizer and Novartis and clinical trial support from Novartis and Astellas, outside of the submitted work. P.H. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work shares in TSI, a university company with an interest in molecular diagnostics. W.B. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. G.O. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work D.S. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work J.G. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. A.L. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. D.K. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work CM. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. M.C. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. A.J. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, Opsona Therapeutics, AstraZeneca, Bayer and Pfizer, outside the submitted work. L.G. reports personal fees from Astellas during the conduct of the study for acting as a conference speaker; personal fees from Astellas, personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, outside the submitted work. B.F. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, grants from BMS, grants and consulting fees from Pharmalink, and lecturing fees from Sandoz, outside of the submitted work. J.O.G. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. J.P. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. J.O.L. reports nonfinancial support from Astellas, during the development this supplement; nonfinancial support and personal fees from Astellas, personal fees from Novartis, and grants from Fisher Scientific, outside of the submitted work. V.A. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. P.T. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. U.B. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support from and personal fees from Astellas, outside the submitted work. J.N. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, and personal fees from Novartis, outside of the submitted work; employment as a consultant physician at Queen Elizabeth Hospital, Birmingham. A.S.-G. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support and personal fees from Astellas, outside of the submitted work. E.G. reports nonfinancial support from Astellas, during the development of this supplement; nonfinancial support from Astellas, and personal fees from Astellas, Pfizer and Novartis, outside the submitted work. M.M. reports nonfinancial support from Astellas, during the development of this supplement; non-financial support and personal fees from Astellas, outside of the submitted work. M.G. reports nonfinancial support from Astellas during the development of this supplement; nonfinancial support from Astellas and personal fees from Astellas, outside the submitted work.

Original languageEnglish (US)
Pages (from-to)S1-S41
JournalTransplantation
Volume101
Issue number2
DOIs
StatePublished - 2017

ASJC Scopus subject areas

  • Transplantation

Fingerprint

Dive into the research topics of 'Advancing transplantation: New questions, new possibilities in kidney and liver transplantation'. Together they form a unique fingerprint.

Cite this